Stockreport

Rapport Therapeutics Announces New Data and Post Hoc Analysis Demonstrating the Magnitude and Consistency of RAP-219’s Clinical Response in Patients with Focal Onset Seizures

Rapport Therapeutics, Inc.  (RAPP) 
PDF Post-hoc analysis of RAP-219 Phase 2a data showed early onset of action and consistency of median response over the entire treatment period, along with consistent effica [Read more]